Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
02/2010
02/23/2010US7666848 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics
02/23/2010US7666626 P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi)
02/23/2010US7666418 Method for treating Th2-mediated disease
02/23/2010CA2442974C Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases
02/18/2010WO2010019839A1 Methods for using interferon gamma to absorb fluid from the subretinal space
02/18/2010WO2010019536A1 Therapeutic compounds
02/18/2010WO2010018837A2 Protein cross-linking inhibitor
02/18/2010WO2010018836A2 Polyglutamine aggregation inhibitor
02/18/2010WO2010018800A1 Acetyl pyrrolidinyl indole derivative
02/18/2010WO2010017626A1 Compositions comprising terpene compounds for treating negative sensory phenomena
02/18/2010WO2010017598A1 Anti-il-12/il-23 antibodies
02/18/2010WO2009154873A9 Use of novel lipid mediators to inhibit angiogenesis
02/18/2010WO2009137303A3 Use of extracts of capraria biflora in the prevention and/or treatment of senile cataracts
02/18/2010US20100041715 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof
02/18/2010US20100041671 Methods for treating glaucoma
02/18/2010US20100041660 Novel 2-pyridinecarboxamide derivatives
02/18/2010US20100041651 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
02/18/2010US20100041634 N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy
02/18/2010US20100041628 Novel indole derivative having ikappab kinase beta inhibitory activity
02/18/2010US20100041624 Buprenorphine formulations for intranasal delivery
02/18/2010US20100041072 Process for identifying a ligand that binds to the nep binding site for the smr1 pentapeptide
02/18/2010US20100040604 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
02/18/2010US20100040537 antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases
02/18/2010CA2734185A1 Methods for using interferon gamma to absorb fluid from the subretinal space
02/18/2010CA2733926A1 Therapeutic compounds
02/18/2010CA2733646A1 Acetyl pyrrolidinyl indole derivative
02/18/2010CA2733642A1 Anti-il-12/il-23 antibodies
02/18/2010CA2732784A1 Compositions comprising terpene compounds for treating negative sensory phenomena
02/17/2010EP2153842A1 Prevention and treatment of drug-associated ocular side effects with a cyclosporin
02/17/2010EP2153819A2 Compositions containing therapeutically active components having enhanced solubility
02/17/2010EP2152755A1 Prevention and treatment of complement-associated eye conditions
02/17/2010EP2152292A1 Angiogenesis inhibitor comprising meteorin as an active ingredient
02/17/2010EP2152291A1 Use of cyclosporines in the treatment of patients with intraocular lenses
02/17/2010EP1511737B1 Aryloximes
02/17/2010CN100589809C Quaternised ammonium cyclodextrin compounds
02/16/2010US7662826 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
02/16/2010US7662796 Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
02/16/2010US7662794 DNA enzyme to inhibit plasminogen activator inhibitor-1
02/16/2010CA2440037C Benzimidazole derivatives for modulating the rage receptor
02/16/2010CA2429109C Anti-inflammatory agents
02/16/2010CA2407043C Naphthamidine urokinase inhibitors
02/16/2010CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
02/16/2010CA2346082C Tricyclic .delta.3-piperidines as pharmaceuticals
02/11/2010WO2010017541A2 Compositions and methods for treatment of neurodegenerative disease
02/11/2010WO2010017100A1 Treatment of excess cerumen secretion
02/11/2010WO2010016044A1 Treatment of retinal degeneration
02/11/2010WO2010016043A1 Treatment of retinal degeneration
02/11/2010WO2010016042A1 Treatment of retinal degeneration
02/11/2010WO2010015792A1 Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
02/11/2010WO2010015672A1 Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye
02/11/2010WO2010015528A1 New no-releasing steroids for the treatment of retina and macula lutea diseases
02/11/2010US20100036000 Controlled release antimicrobial compositions and methods for the treatment of otic disorders
02/11/2010US20100035993 Methods and compositions comprising 2-[(3-chlorophenyl) amino] phenylacetic acid for hyperpermeability and neovascularization disorders of the retina
02/11/2010US20100035986 Methods for the treatment and prevention of age-related retinal dysfunction
02/11/2010US20100035969 connective tissue growth factor (CTGF) expression inhibition; treating glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing
02/11/2010US20100035943 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
02/11/2010US20100035891 Pharmaceutically Active Compounds
02/11/2010US20100035870 Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds
02/11/2010US20100035865 Sulfonamides and Pharmaceutical Compositions Thereof
02/11/2010US20100034853 Compositions of activated botulinum toxin type B
02/11/2010US20100034823 Crystalline anti-hTNFalpha antibodies
02/11/2010US20100034811 Therapeutic agents for diseases involving choroidal neovascularization
02/11/2010US20100034795 Use of l-carnitine or alkanyl l-carnitine for the preparation of a dietary supplement or medicament for the treatment of corneal disease
02/11/2010US20100034749 Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
02/11/2010CA2731520A1 New no-releasing steroids for the treatment of retina and macula lutea diseases
02/10/2010EP2151454A2 Platelet-derived growth factor D, DNA coding therefor, and uses thereof
02/10/2010EP2151438A1 Pharmaceutical containing ppar agonist
02/10/2010EP2151436A1 Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
02/10/2010EP2150244A1 Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
02/10/2010EP2150117A1 Methods and compositions for mitochondrial replacement therapy
02/10/2010CN100588647C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
02/10/2010CN100588644C Eugenol ibuprofen ester medical compound and its preparation and preparation method
02/09/2010US7659407 Pharmaceutical compounds
02/09/2010US7659269 Substituted indolealkanoic acids
02/09/2010US7659115 Nucleic acid encoding human transductin-1 polypeptide
02/09/2010CA2484954C 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
02/09/2010CA2473394C Semi-fluorinated alkanes and their use
02/09/2010CA2449488C Compositions and methods for treating hyperimmune response in the eye
02/09/2010CA2440760C Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
02/09/2010CA2439593C Heterocyclic compounds for aging-related and diabetic vascular complications
02/09/2010CA2438704C Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof
02/09/2010CA2413061C Serine protease inhibitors
02/09/2010CA2192092C Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
02/09/2010CA2150933C Glaucoma treatment
02/04/2010WO2010013494A1 Pharmaceutical composition comprising botulinum neurotoxin preparation incapable of being synaptically transported, and use thereof
02/04/2010WO2010012567A1 Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology
02/04/2010WO2009135135A3 Fibromodulin formulation for reducing corneal scarring
02/04/2010US20100031379 Non-human animal for eye disease model
02/04/2010US20100029746 Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
02/04/2010US20100029735 Therapeutic compounds
02/04/2010US20100029728 Phosphodiesterase inhibitors
02/04/2010US20100029719 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/04/2010US20100029675 Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
02/04/2010US20100029639 Ion channel modulating compounds and uses thereof
02/04/2010US20100029622 Microemulsions
02/04/2010US20100028459 Nutritional supplement composition for treatment of ocular diseases
02/04/2010US20100028407 Layered bio-adhesive compositions and uses thereof
02/04/2010US20100028406 Topical drug delivery by iontophoresis
02/04/2010US20100028349 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity
02/04/2010US20100028328 Topical treatment for diseases of eye surface
1 ... 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 ... 531